74 related articles for article (PubMed ID: 8179244)
21. Pilot study of interferon gamma for chronic hepatitis C.
Soza A; Heller T; Ghany M; Lutchman G; Jake Liang T; Germain J; Hsu HH; Park Y; Hoofnagle JH
J Hepatol; 2005 Jul; 43(1):67-71. PubMed ID: 15913831
[TBL] [Abstract][Full Text] [Related]
22. alpha-Interferon retreatment of patients with chronic hepatitis C.
Rabinovitz M; Block G; Finkelstein SD
Am J Gastroenterol; 1996 Aug; 91(8):1523-6. PubMed ID: 8759654
[TBL] [Abstract][Full Text] [Related]
23. [Effectiveness of antiviral treatment of patients with chronic hepatitis C (a Polish multicenter study)].
Juszczyk J; Bolewska B; Flieger J; Swietek K; Adamek B; Biskupska-Karasińska M; Dziambor AP; Boroń-Kaczmarska A; Wawrzynowicz-Syczewska M; Cianciara J; Kozłowska J; Daniluk J; Słomka M; Dudziak M; Zaborowski P; Gładysz A; Piszko P; Gonciarz Z; Mazur W; Machniak M; Kryczka W; Zarebska-Michaluk D; Trocha H; Witczak-Malinowska K; Lakomy E; Kuydowicz J; Niwicka-Michałowska A
Pol Merkur Lekarski; 2001 Oct; 11(64):340-3. PubMed ID: 11770315
[TBL] [Abstract][Full Text] [Related]
24. Clinical experiences with interferon-alpha and interferon-gamma.
Steinmann GG; Rosenkaimer F; Leitz G
Int Rev Exp Pathol; 1993; 34 Pt B():193-207. PubMed ID: 8458713
[No Abstract] [Full Text] [Related]
25. [Treatment of chronic hepatitis with interferon in children with kidney diseases].
Szczepańska M; Tobis A; Schneiberg B; Szprynger K; Kobos E; Morawiec-Knysak A
Pol Merkur Lekarski; 2005 Jan; 18(103):22-8. PubMed ID: 15859541
[TBL] [Abstract][Full Text] [Related]
26. Interferons. New additions and indications for use.
Stadler R; Ruszczak Z
Dermatol Clin; 1993 Jan; 11(1):187-99. PubMed ID: 7679614
[TBL] [Abstract][Full Text] [Related]
27. Immunomodifiers applicable to the prevention and management of infectious diseases in children.
La Pine TR; Hill HR
Adv Pediatr Infect Dis; 1994; 9():37-58. PubMed ID: 8123225
[TBL] [Abstract][Full Text] [Related]
28. Ribavirin dose modification based on renal function is necessary to reduce hemolysis in liver transplant patients with hepatitis C virus infection.
Jain AB; Eghtesad B; Venkataramanan R; Fontes PA; Kashyap R; Dvorchik I; Shakil AO; Kingery L; Fung JJ
Liver Transpl; 2002 Nov; 8(11):1007-13. PubMed ID: 12424713
[TBL] [Abstract][Full Text] [Related]
29. [Alpha-interferons in the treatment of patients with chronic myeloid leukemia].
Abdulkadyrov KM; Udal'eva VIu; Rukavitsyn OA; Bessmel'tsev SS
Vopr Onkol; 1999; 45(4):387-92. PubMed ID: 10532097
[TBL] [Abstract][Full Text] [Related]
30. [Treatment with growth factors and cytokines in hematologic diseases].
Waage A; Dahl IM; Evensen SA; Holte H; Lamvik J; Sletnes K; Wisløff F
Tidsskr Nor Laegeforen; 1996 May; 116(12):1465-9. PubMed ID: 8650635
[TBL] [Abstract][Full Text] [Related]
31. Combination therapy with amantadine and interferon in naïve patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials.
Mangia A; Leandro G; Helbling B; Renner EL; Tabone M; Sidoli L; Caronia S; Foster GR; Zeuzem S; Berg T; Di Marco V; Cino N; Andriulli A
J Hepatol; 2004 Mar; 40(3):478-83. PubMed ID: 15123363
[TBL] [Abstract][Full Text] [Related]
32. Interest of interferon alpha in systemic mastocytosis. The French experience and review of the literature.
Simon J; Lortholary O; Caillat-Vigneron N; Raphaël M; Martin A; Brière J; Barète S; Hermine O; Casassus P;
Pathol Biol (Paris); 2004 Jun; 52(5):294-9. PubMed ID: 15217717
[TBL] [Abstract][Full Text] [Related]
33. Studies of the effectiveness of interferon alpha treatment for chronic hepatitis C in children.
Czerwionka-Szaflarska M; Chrobot A; Szaflarska-Szczepanik A
Med Sci Monit; 2000; 6(5):964-70. PubMed ID: 11208439
[TBL] [Abstract][Full Text] [Related]
34. [Clinical value of interferon-alpha in the treatment of malignant hematologic diseases].
Harousseau JL
Presse Med; 1997 May; 26(18):857-9. PubMed ID: 9207887
[TBL] [Abstract][Full Text] [Related]
35. [The use of interferon-alpha in hematological diseases].
Nerl C
Dtsch Med Wochenschr; 1995 Sep; 120(36):1209-11. PubMed ID: 7671773
[No Abstract] [Full Text] [Related]
36. Interferon in haematological disorders.
de Mel C
Ceylon Med J; 1991 Mar; 36(1):4-6. PubMed ID: 1716527
[No Abstract] [Full Text] [Related]
37. [Efficacy of interferon alpha in a case of systemic mastocytosis].
Fain O; Sitbon M; Sibony M; Frilay Y; Mathieu E; Lejeune F; Thomas M
Ann Med Interne (Paris); 1995; 146(3):205-6. PubMed ID: 7653932
[No Abstract] [Full Text] [Related]
38. The Biological Effect of the NanoTiO2and Its Toxicity.
Xiao-Feng P; Lewei L; Zhi Hong L; Qiang Z
Conf Proc IEEE Eng Med Biol Soc; 2005; 2005():1244-7. PubMed ID: 17282419
[TBL] [Abstract][Full Text] [Related]
39. [Interferons 50 years and liver diseases].
Zhang DF
Zhonghua Gan Zang Bing Za Zhi; 2007 Nov; 15(11):801-3. PubMed ID: 18073059
[No Abstract] [Full Text] [Related]
40. Generation of 1.5-mu m radiation through intracavity solid-state Raman shifting in Ba(NO3)2 nonlinear crystals.
Murray JT; Powell RC; Peyghambarian N; Smith D; Austin W; Stolzenberger RA
Opt Lett; 1995 May; 20(9):1017. PubMed ID: 19859409
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
